• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lantus (insulin glargine [rDNA origin] injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lantus (insulin glargine [rDNA origin] injection)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Lantus is a sterile solution of insulin glargine for use as an injection. The primary activity of insulin is regulation of glucose metabolism. Insulin and its analogs lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

    Lantus is specifically indicated for once-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

    Lantus is supplied as 10 mL vials, 3 mL cartridges or as a 3 mL SoloStar disposable insulin device, all designed for subcutaneous administration. Lantus should be administered subcutaneously once a day at the same time every day. The desired blood glucose levels as well as the doses and timing of antidiabetes medications must be determined individually.

    Clinical Results

    FDA Approval
    The FDA approval of Lantus was based on the following trials:

    Type 1 Diabetes-Adults
    Study A
    This randomized, controlled study enrolled 585 subjects who were randomized to basal-bolus treatment with Lantus (once daily at bedtime) or to NPH human insulin (once daily in the morning or at bedtime or twice daily at bedtime) and treated for 28 weeks. Regular human insulin was administered before each meal. The results were as follows:
    HbA1c adjusted mean change from baseline: Lantus +0.21 and NPH +0.10.
    the basal insulin dose mean change from baseline: Lantus -1.7 and NPH -0.3
    the total insulin dose mean change from baseline: Lantus -1.1 NPH -0.1
    the adjusted mean change from baseline in fasting blood glucose (mg/dL): Lantus -21.1 and NPH -16.0.
    Study B
    This randomized, controlled study enrolled 534 subjects who were randomized to basal-bolus treatment with Lantus (once daily at bedtime) or to NPH human insulin (once daily in the morning or at bedtime or twice daily at bedtime) and treated for 28 weeks. Regular human insulin was administered before each meal. The results were as follows:
    HbA1c adjusted mean change from baseline: Lantus -0.16 and NPH -0.21.
    the basal insulin dose mean change from baseline: Lantus -4.1 and NPH +1.8
    the total insulin dose mean change from baseline: Lantus +0.3 NPH +3.7
    the adjusted mean change from baseline in fasting blood glucose (mg/dL): Lantus -20.2 and NPH -16.9.
    Study C
    This randomized, controlled clinical study enrolled 619 subjects with type 1 diabetes who were treated for 16 weeks with a basal-bolus insulin regimen where insulin lispro was used before each meal. Lantus was administered once daily at bedtime and NPH human insulin was administered once or twice daily. The results were as follows:
    HbA1c adjusted mean change from baseline: Lantus -0.07 and NPH -0.08
    the basal insulin dose mean change from baseline: Lantus -4.5 and NPH +0.9
    the total insulin dose mean change from baseline: Lantus -2.9 NPH +0.3
    the adjusted mean change from baseline in fasting blood glucose (mg/dL): Lantus -29.3 and NPH -11.9

    Type 1 Diabetes–Pediatric
    Study D
    This randomized, controlled clinical study enrolled 349 pediatric patients (age range 6 to 15 years) with type 1 diabetes> The subjects were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Lantus was administered once daily at bedtime and NPH human insulin was administered once or twice daily. The results were as follows:
    HbA1c adjusted mean change from baseline: Lantus +0.28 and NPH +0.27
    the basal insulin dose mean change from baseline: Lantus -1.3 and NPH +2.4
    the total insulin dose mean change from baseline: Lantus +1.9 NPH +3.4
    the adjusted mean change from baseline in fasting blood glucose (mg/dL): Lantus -23.2 and NPH -12.2.

    Type 2 Diabetes–Adult
    Study E
    This randomized, controlled clinical study enrolled 570 siubjects. Lantus was evaluated for 52 weeks as part of a regimen of combination therapy with insulin and oral antidiabetes agents (a sulfonylurea, metformin, acarbose, or combinations of these drugs). Lantus administered once daily at bedtime was as effective as NPH human insulin administered once daily at bedtime in reducing glycohemoglobin and fasting glucose. The results were as follows:
    HbA1c adjusted mean change from baseline: Lantus -0.46 and NPH -0.38
    the basal insulin dose mean change from baseline: Lantus +11.5 and NPH +9.0
    the total insulin dose mean change from baseline: Lantus +11.5 NPH +9.0
    the adjusted mean change from baseline in fasting blood glucose (mg/dL): Lantus -49.0 and NPH -46.3.
    Study F
    This randomized, controlled clinical study enrolled 518 patients with type 2 diabetes not using oral antidiabetes agents. The subjects received a basal-bolus regimen of Lantus once daily at bedtime or NPH human insulin administered once or twice daily for 28 weeks. Regular human insulin was used before meals as needed. Lantus had similar effectiveness as either once- or twice-daily NPH human insulin in reducing glycohemoglobin and fasting glucose with a similar incidence of hypoglycemia. The results were as follows:
    HbA1c adjusted mean change from baseline: Lantus -0.41 and NPH -0.59
    the basal insulin dose mean change from baseline: Lantus -1.2 and NPH +7.0
    the total insulin dose mean change from baseline: Lantus +10.0 NPH +11.1
    the adjusted mean change from baseline in fasting blood glucose (mg/dL): Lantus -23.8 and NPH -21.6

    Lantus Flexible Daily Dosing
    Study G
    This randomized, controlled clinical study enrolled 378 subjects with type 1 diabetes. Lantus was administered pre-breakfast, pre-dinner, or at bedtime. Subjects were also treated with insulin lispro at mealtime. Lantus administered at different times of the day resulted in similar reductions in glycated hemoglobin compared to that with bedtime administration.
    Study H
    This randomized, active-controlled study enrolled 697 subjects with type 2 diabetes no longer adequately controlled on oral agent therapy. Lantus was administered pre-breakfast or at bedtime; a subjects also received AMARYL (glimeperide) 3 mg daily. Lantus given before breakfast was at least as effective in lowering glycated hemoglobin A1c (HbA1c) as Lantus given at bedtime or NPH human insulin given at bedtime.

    Side Effects

    Adverse events associated with the use of Lantus may include, but are not limited to, the following:

    • Hypoglycemia
    • Renal impairment
    • Hepatic impairment
    • Allergic Reactions
    • Injection Site Reactions

    Mechanism of Action

    Lantus is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. Lantus is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli as the production organism. The primary activity of insulin is regulation of glucose metabolism. Insulin and its analogs lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

    Additional Information

    For additional information regarding Lantus or type I or type II diabetes, please visit the Lantus web page.

    Approval Date: 2000-04-01
    Company Name: Sanofi-aventis
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing